These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1988303)

  • 1. Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b.
    Aul C; Gattermann N; Schneider W
    Eur J Haematol; 1991 Jan; 46(1):11-6. PubMed ID: 1988303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor.
    Hofmann WK; Ganser A; Seipelt G; Ottmann OG; Zander C; Geissler G; Hoffmann K; Höffken K; Fischer JT; Isele G; Hoelzer D
    Ann Hematol; 1999 Mar; 78(3):125-30. PubMed ID: 10211754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results.
    Elias L; Hoffman R; Boswell S; Tensen L; Bonnem EM
    Leukemia; 1987 Feb; 1(2):105-10. PubMed ID: 3478534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide for the treatment of patients with myelodysplastic syndromes.
    Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
    Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-interferon in myelodysplasia; clinical observations and effects on NK cells.
    Galvani DW; Nethersell AB; Cawley JC
    Leuk Res; 1988; 12(3):257-62. PubMed ID: 3163399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
    Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
    Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose etoposide: a potential therapy for myelodysplastic syndromes.
    Ogata K; Yamada T; Ito T; Gomi S; Tanabe Y; Ohki I; Dan K; Nomura T
    Br J Haematol; 1992 Oct; 82(2):354-7. PubMed ID: 1419818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
    Ribrag V; Suzan F; Ravoet C; Feremans W; Guerci A; Dreyfus F; Damaj G; Vantelon JM; Bourhis JH; Fenaux P
    Leukemia; 2003 Feb; 17(2):319-22. PubMed ID: 12592329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
    Fenaux P; Morel P; Rose C; Lai JL; Jouet JP; Bauters F
    Br J Haematol; 1991 Apr; 77(4):497-501. PubMed ID: 2025575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
    Bergsagel DE; Messner H
    Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.
    Gilbert HS
    Cancer; 1998 Sep; 83(6):1205-13. PubMed ID: 9740087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant interferon-alpha-2b treatment of hairy-cell leukaemia: experience with a low-dose schedule.
    Hasselbalch H; Braide I; Lisse I; Röckert LL; Swolin B; Carneskog J; Hagberg H; Hippe E; Jensen MK; Lundin P
    Eur J Haematol; 1988 Nov; 41(5):438-44. PubMed ID: 3061836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes: analysis of morphological features related to the FAB-classification.
    van der Weide M; Sizoo W; Krefft J; Langenhuijsen MM
    Eur J Haematol; 1988 Jul; 41(1):58-61. PubMed ID: 2456946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals.
    Strupp C; Gattermann N; Giagounidis A; Aul C; Hildebrandt B; Haas R; Germing U
    Leuk Res; 2003 May; 27(5):397-404. PubMed ID: 12620291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany.
    Creutzig U; Cantù-Rajnoldi A; Ritter J; Romitti L; Odenwald E; Conter V; Riehm H; Masera G
    Am J Pediatr Hematol Oncol; 1987; 9(4):324-30. PubMed ID: 3439582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.
    Bennett JM; Young MS; Liesveld JL; Paietta E; Miller KB; Lazarus HM; Marsh RD; Friedenberg WR; Saba HT; Hayes FA; Dewald GW; Hiddemann W; Rowe JM
    Am J Hematol; 2001 Jan; 66(1):23-7. PubMed ID: 11426487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
    Venditti A; Tamburini A; Buccisano F; Scimò MT; Del Poeta G; Maurillo L; Cox MC; Abruzzese E; Tribalto M; Masi M; Amadori S
    Ann Hematol; 2000 Mar; 79(3):138-42. PubMed ID: 10803936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
    Omine M; Yamauchi H
    Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.